SCLX

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: TEVA BHC PRGO RDY AMPH PFE ABBV MRK NBIX

| Held by: VTI VXF IWC ITOT CSML BTEC URTY UWM QQQS DFAU

Index	-	P/E	-	EPS (ttm)	-12.12	Insider Own	21.46%	Shs Outstand	5.50M	Perf Week	15.26%
Market Cap	182.91M	Forward P/E	8.45	EPS next Y	3.11	Insider Trans	0.00%	Shs Float	5.46M	Perf Month	25.14%
Enterprise Value	228.18M	PEG	-	EPS next Q	-0.41	Inst Own	8.98%	Short Float	9.76%	Perf Quarter	406.36%
Income	-122.99M	P/S	4.13	EPS this Y	-464.67%	Inst Trans	-45.05%	Short Ratio	2.59	Perf Half Y	162.72%
Sales	44.24M	P/B	-	EPS next Y	188.60%	ROA	-130.63%	Short Interest	0.53M	Perf YTD	76.09%
Book/sh	-45.29	P/C	44.61	EPS next 5Y	-	ROE	-	52W High	41.30 -36.37%	Perf Year	-30.48%
Cash/sh	0.59	P/FCF	8.69	EPS past 3/5Y	5.86% -	ROIC	-	52W Low	3.60 630.00%	Perf 3Y	-92.73%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	21.80% -	Gross Margin	61.26%	Volatility	9.99% 11.70%	Perf 5Y	-
Dividend TTM	-	EV/Sales	5.16	EPS Y/Y TTM	66.01%	Oper. Margin	-224.04%	ATR (14)	2.06	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.07	Sales Y/Y TTM	-12.98%	Profit Margin	-278.03%	RSI (14)	76.74	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.08	EPS Q/Q	32.18%	SMA20	29.98%	Beta	1.39	Target Price	630.00
Payout	-	Debt/Eq	-	Sales Q/Q	-39.55%	SMA50	75.00%	Rel Volume	1.66	Prev Close	25.36
Employees	115	LT Debt/Eq	-	Earnings	Sep 03	SMA200	123.17%	Avg Volume	206.01K	Price	26.28
IPO	Mar 05, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% 0.00%	Trades		Volume	342,892	Change	3.63%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-27-25	Initiated	D. Boral Capital	Buy	$22
Oct-16-24	Initiated	Alliance Global Partners	Buy	$14
Jun-13-24	Initiated	Rodman & Renshaw	Buy	$13
Oct-16-23	Initiated	B. Riley Securities	Buy	$4
Oct-13-23	Initiated	B. Riley Securities	Buy	$4
Oct-09-23	Initiated	H.C. Wainwright	Buy	$12

Sep-04-25 09:00AM	Semnur Pharmaceuticals, Inc. ("Semnur"), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, "Scilex"), and Denali Capital Acquisition Corp. Announce Approval from Denali's Shareholders of the Previously Announced Business Combination (GlobeNewswire) +8.06%
Aug-21-25 06:00AM	Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. ("Semnur"), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16.00 per share and Jaisim Shah, Scilex's CEO and President, Will be Dedicated to Semnur on a Full Time Basis to Rapidly Advance SP-102 to Regulatory Approval and Commercialization for the Treatment of Lumbosacral Radicular Pain (LRP)/Sciatica (GlobeNewswire)
Aug-13-25 06:00AM	Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex (GlobeNewswire) +18.85%
Jun-23-25 04:50PM	Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board (GlobeNewswire) +10.44%
Jun-05-25 12:05PM	Scilex Holding Company Announces Publication on GLOPERBA Dosing Adjustments in Peer-Review Journal (GlobeNewswire) -7.17%
09:00AM	Loading…
May-16-25 09:00AM	Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL (GlobeNewswire)
May-01-25 09:00AM	Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL. (GlobeNewswire) +7.59%
Apr-30-25 01:46PM	Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule (GlobeNewswire)
Apr-22-25 09:00AM	Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025 (GlobeNewswire) -15.11%
Apr-16-25 02:12PM	Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis (GlobeNewswire) -11.56%
Apr-15-25 09:00AM	Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB 's Acute Treatment of Migraine With or Without Aura in Canada (GlobeNewswire)
Apr-12-25 09:51AM	Scilex downgraded to Hold from Buy at D. Boral Capital (TipRanks)
Apr-11-25 09:00AM	Scilex Holding Company Announces 1-for-35 Reverse Stock Split (GlobeNewswire) -21.53%
Mar-26-25 08:24PM	Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva (GlobeNewswire)
Mar-10-25 09:00AM	Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025 (GlobeNewswire)
09:00AM	Loading…
Jan-31-25 09:00AM	Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025 (GlobeNewswire) -6.39%
Jan-22-25 08:00AM	Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB in Acute Pain Indication (GlobeNewswire)
Jan-21-25 11:49AM	Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) (GlobeNewswire) -5.79%
09:46AM	Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025 (GlobeNewswire)
09:00AM	Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC (GlobeNewswire)
07:00AM	Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB in Acute Pain Indication (GlobeNewswire)
06:00AM	Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024 (GlobeNewswire)
Jan-16-25 03:38PM	Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba , an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults (GlobeNewswire) +5.25%
Jan-14-25 09:22AM	Scilex announces Pain Medicine News published data on ZTildo vs Lidocaine 5% (TipRanks)
Jan-13-25 09:00AM	Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido vs. Lidocaine 5% Patch (GlobeNewswire)
Jan-08-25 04:00PM	Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination (GlobeNewswire) -5.77%
Dec-30-24 09:00AM	Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025 (GlobeNewswire) +7.97%
Dec-16-24 09:00AM	Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation (GlobeNewswire)
Dec-13-24 12:23PM	Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering (GlobeNewswire)
Dec-12-24 08:21AM	Scilex Holding Company Announces $17 Million Registered Direct Offering (GlobeNewswire) -12.75%
12:49PM	Loading…
Dec-11-24 12:49PM	Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer's Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025 (GlobeNewswire)
07:30AM	Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor (GlobeNewswire)
Dec-10-24 08:00AM	NeuroBiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 indications; Binding Term Sheet Includes Collaboration for Development and Commercialization of Novel Oral Tablet KDS2010 in Ongoing Phase 2 CardioMetabolic and Neurodegenerative Diseases (GlobeNewswire) -16.36%
07:00AM	Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and Neurodegenerative Diseases Including Alzheimer's Disease (GlobeNewswire)
Nov-22-24 06:00AM	Scilex Holding Company Announces Receipt of Notice from Nasdaq (GlobeNewswire) -5.57%
Nov-15-24 09:00AM	Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 19, 2024 (GlobeNewswire) -10.31%
Nov-11-24 05:01PM	Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination (GlobeNewswire) -9.01%
Nov-06-24 12:24PM	Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali (GlobeNewswire)
Oct-30-24 06:00AM	Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms (GlobeNewswire) -5.35%
Oct-29-24 06:00AM	Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock (GlobeNewswire)
Oct-28-24 06:00AM	Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary (GlobeNewswire) +14.05%
Oct-16-24 07:00AM	Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals Inc. Scilex Pharmaceuticals Commercial Products Include Three Non-Opioid Approved Products and Pipeline of Phase 3 Ready SP-103 With Greater Than a $1.0 Billion Revenue Potential (GlobeNewswire) +7.67%
04:00AM	Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion (GlobeNewswire)
Oct-08-24 01:58PM	Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024 (GlobeNewswire) -8.34%
11:50AM	Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing (GlobeNewswire)
Oct-07-24 10:00AM	Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt (PR Newswire) -6.55%
09:52AM	Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile (GlobeNewswire)
Sep-26-24 09:00AM	Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025 (GlobeNewswire) +12.51%
Sep-18-24 09:00AM	Scilex Holding Company Announces the Continuing Support from Endeavor Distribution LLC in the Multi-Year Agreement for Scilex's Commercial Products and the Satisfaction of FSF 33433 LLC $10 Million Loan (GlobeNewswire)
Sep-12-24 09:00AM	Scilex Holding Company Announces It Has Received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy (NABP ) (GlobeNewswire)
Sep-09-24 09:00AM	Scilex Holding Company to Present at the 26th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
Sep-05-24 09:00AM	Scilex Holding Company Announces Acceptance of Presentation at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 19, 2024 (GlobeNewswire)
Sep-03-24 09:00AM	Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination (GlobeNewswire)
09:00AM	Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion (GlobeNewswire)
Aug-30-24 09:00AM	Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024 (GlobeNewswire)
Aug-29-24 09:00AM	Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA Label (GlobeNewswire)
Aug-21-24 09:00AM	Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB Patent Related to the Treatment of Acute Pain (GlobeNewswire)
Aug-09-24 09:00AM	Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa (GlobeNewswire)
Aug-01-24 09:00AM	Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended July 31, 2024 (GlobeNewswire) -5.66%
Jul-24-24 10:52AM	Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report (GlobeNewswire)
Jul-23-24 09:00AM	Scilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D. (GlobeNewswire)
Jul-17-24 09:00AM	Scilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics' R&D Expertise and Local Market Connections to Support the Expansion of ZTlido Program in ex-US and Potentially Provide Additional Access to Patients in Certain Key Markets in Far East Region (GlobeNewswire)
Jul-03-24 07:21AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -6.74%
Jul-02-24 05:15PM	Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination (GlobeNewswire)
09:00AM	Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York (GlobeNewswire)
Jul-01-24 09:00AM	Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024 (GlobeNewswire)
Jun-20-24 09:00AM	Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC. (GlobeNewswire) +7.10%
Jun-14-24 01:41PM	Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA ) in Lumbosacral Radicular Pain (Sciatica) (GlobeNewswire) +8.05%
Jun-13-24 09:00AM	Scilex Holding Company to Present Poster on ELYXYB (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be Held in San Diego, CA on June 13-16, 2024 (GlobeNewswire)
Jun-11-24 07:20PM	Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies (GlobeNewswire) +18.75% +8.27%
09:00AM	Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA (GlobeNewswire)
Jun-10-24 11:49AM	Scilex Holding Company Announces Stocking of GLOPERBA is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S. (GlobeNewswire)
Jun-06-24 02:56PM	Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba which will be launched in the US in the week of June 10th 2024 (GlobeNewswire) +9.26%
May-30-24 01:19PM	Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding Company (GlobeNewswire)
May-24-24 01:40PM	Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index (GlobeNewswire)
09:00AM	Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company (GlobeNewswire)
May-14-24 09:00AM	Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's intent to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba (GlobeNewswire)
08:53AM	SCLX Stock Earnings: Scilex Holding Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-13-24 09:00AM	Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock (GlobeNewswire) +7.98%
Apr-25-24 04:01PM	Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering (GlobeNewswire)
Apr-24-24 08:00AM	Scilex Holding Company Announces $15 Million Registered Direct Offering (GlobeNewswire) -12.97%
Apr-16-24 09:00AM	Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses (GlobeNewswire) -9.38%
Apr-09-24 09:00AM	Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido and ELYXYB for Commercially Insured Patients and the addition of ELYXYB to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool (GlobeNewswire)
Mar-27-24 09:00AM	Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend (GlobeNewswire) +6.62%
Mar-21-24 09:30AM	Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients (GlobeNewswire)
Mar-20-24 11:00AM	Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed (GlobeNewswire)
09:00AM	Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba (GlobeNewswire)
Mar-19-24 09:00AM	Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation (GlobeNewswire)
Mar-18-24 09:00AM	Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB for Acute Treatment of Migraine With or Without Aura in Canada (GlobeNewswire)
Mar-15-24 02:45PM	Scilex Holding Announces Issuance of Halal Certification for its ZTlido product by Circle H International, Inc. (GlobeNewswire)
09:00AM	Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement (GlobeNewswire)
Mar-05-24 04:01PM	Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering (GlobeNewswire)
09:00AM	Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba , its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the First Half of 2024 (GlobeNewswire)
Mar-04-24 09:00AM	Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates (GlobeNewswire)
Mar-02-24 03:25PM	Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024 (GlobeNewswire)
Feb-29-24 05:32PM	Scilex Holding Company Announces $10 Million Bought Deal Offering (GlobeNewswire) -6.20% -41.19%
Feb-28-24 09:00AM	Scilex Holding Company Announces Major Initiative with a Leading National Pharmacy Chain to Stock GLOPERBA in Most of Their Stores Throughout the U.S. (GlobeNewswire)
Feb-27-24 09:00AM	Scilex Holding Company Announces Acceptance of Abstract for Poster and Oral Presentation at the Annual Meeting of the American Academy of Pain Medicine (AAPM) (GlobeNewswire) +11.59%
Feb-26-24 04:53PM	Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement (GlobeNewswire) +18.29%
09:00AM	Scilex Holding Company Announces that ZTlido Achieves a Major Milestone - Over One Million Patients Treated Since its Launch - and Two Additional Milestones Met (GlobeNewswire)

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SHAH JAISIM	See Remarks	Dec 18 '24	Buy	0.46	30,000	13,800	139,333	Dec 18 07:04 PM
Ji Henry	Executive Chairperson	Oct 31 '24	Buy	0.94	8,888	8,351	320,161	Oct 31 12:44 PM
SHAH JAISIM	See Remarks	Oct 29 '24	Buy	0.99	32,000	31,670	109,333	Oct 29 06:59 PM
Followwill Dorman	Director	Oct 18 '24	Buy	0.99	1,000	990	2,300	Oct 18 04:29 PM
Chun Jay	Director	Oct 18 '24	Buy	0.95	5,000	4,750	112,500	Oct 18 04:29 PM
Wu Yue Alexander	Director	Oct 17 '24	Buy	0.95	20,000	18,992	25,000	Oct 18 09:14 AM
Lemus David	Director	Oct 17 '24	Buy	0.90	2,000	1,800	2,000	Oct 18 09:10 AM
Ji Henry	Executive Chairperson	Oct 17 '24	Buy	0.97	10,000	9,710	60,070	Oct 18 09:08 AM
SHAH JAISIM	See Remarks	Oct 16 '24	Buy	0.99	30,000	29,751	77,333	Oct 17 12:44 PM
Ma Stephen Hoi	Chief Financial Officer	Oct 16 '24	Buy	0.97	6,700	6,499	22,840	Oct 17 11:09 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Scilex Holding Company

Upgrade your FINVIZ experience